Medicopharma

Medicofarma Biotech is a Polish biopharmaceutical company specializing in the development of innovative therapies for oncology and gastrointestinal disorders. Headquartered in Radom with research centers in Poznań and Lublin, the company utilizes its proprietary CANCER PRINT 3D bioprinting platform to create advanced tissue models for drug testing and development. Its primary R&D focus includes first-in-class RNA-based therapeutics for glioblastoma and antisense treatments targeting Tenascin-C in breast and ovarian cancers. Medicofarma Biotech is listed on the NewConnect market of the Warsaw Stock Exchange and maintains strategic collaborations with the Polish Academy of Sciences to advance its pipeline of high-impact medical solutions.